Long term incidence and the molecular basis of hepatitis B resistance to adefovir dipivoxil (ADV)

被引：0
|
作者：
Gibbs, CS
Qi, X
Yang, H
Delaney, WE
Das, K
Arnold, E
Thibault, V
Snow, A
Zhu, Y
Curtis, M
Hadziyannis, S
Westland, CE
Brosgart, CL
Arterburn, S
Miller, MD
Xiong, S
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Rutgers State Univ, CABM, Piscataway, NJ USA
[3] Hosp Pitie Salpetriere, Paris, France
[4] Henry Dunant Hosp, Athens, Greece
来源：
ANTIVIRAL RESEARCH | 2004年 / 62卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
9
引用
收藏
页码：A30 / A30
页数：1
相关论文
共 50 条
  • [1] Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy
    Qi, X
    Snow, A
    Thibault, V
    Zhu, Y
    Curtis, M
    Hadziyannis, SJ
    Brosgart, CL
    Currie, G
    Arterburn, S
    Gibbs, CS
    Miller, MD
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2004, 40 : 20 - 21
  • [2] Long-term adefovir dipivoxil (ADV) demonstrates sustained efficacy in chronic hepatitis B (CHB)
    Brosgart, CL
    Hadziyannis, S
    Benhamou, Y
    Arterburn, S
    Ma, J
    Lu, B
    Xiong, S
    Wollman, M
    James, C
    Chang, CG
    Currie, G
    ANTIVIRAL RESEARCH, 2004, 62 (02) : A47 - A48
  • [3] Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy
    Westland, CE
    Yang, H
    Delaney, WE
    Thibault, V
    Benhamou, Y
    Gibbs, CS
    Miller, MD
    Wulfsohn, M
    Sullivan, M
    Fry, J
    Brosgart, CL
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2003, 38 : 182 - 182
  • [4] Adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B
    Chang, TT
    Lim, SG
    Hadziyannis, S
    Tassopoulos, N
    Tong, M
    Sievert, W
    Shiffman, M
    Jeffers, L
    Goodman, Z
    Wulfsohn, M
    Xiong, S
    James, C
    Fry, J
    Brosgart, C
    Marcellin, P
    GASTROENTEROLOGY, 2002, 123 (01) : 68 - 68
  • [5] Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
    Yeon, J. E.
    Yoo, W.
    Hong, S. P.
    Chang, Y. J.
    Yu, S. K.
    Kim, J. H.
    Seo, Y. S.
    Chung, H. J.
    Moon, M. S.
    Kim, S-O
    Byun, K. S.
    Lee, C. H.
    GUT, 2006, 55 (10) : 1488 - 1495
  • [6] Adefovir dipivoxil/lamivudineDevelopement of adefovir dipivoxil and lamivudine resistance in hepatitis B cirrhosis: case report
    Reactions Weekly, 2017, 1678 (1) : 14 - 14
  • [7] Resistance to adefovir dipivoxil in patients with chronic hepatitis B
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (1): : 4 - 4
  • [8] HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients
    Shiffman, M
    Marcellin, P
    Jeffers, L
    Gordon, S
    Peters, M
    Rizzetto, M
    Buggisch, P
    Vetter, D
    Choy, GS
    Westland, C
    Arterburn, S
    Currie, G
    Brosgart, CL
    JOURNAL OF HEPATOLOGY, 2004, 40 : 17 - 17
  • [9] Genotypic and phenotypic resistance profiles to adefovir dipivoxil in lamivudine-resistant chronic hepatitis B treated with ADV
    Yeon, J
    Yu, S
    Chang, Y
    Lee, J
    Seo, Y
    Yoo, S
    Chung, H
    Jee, M
    Byun, K
    Lee, C
    JOURNAL OF HEPATOLOGY, 2005, 42 : 195 - 196
  • [10] Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)
    Locarnini, S
    Qi, X
    Arterburn, S
    Snow, A
    Brosgart, CL
    Currie, G
    Wulfsohn, M
    Miller, MD
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2005, 42 : 17 - 17
12345